President Donald Trump signed an executive order Thursday reclassifying marijuana as a Schedule III substance with looser restrictions.

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.

Medline priced at $29 per share on Tuesday, raising $6.26 billion to cap off a strong year for new listings and bolster optimism about 2026.

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Pfizer has pursued deals of all sizes to build new revenue streams, but the outlook underscores that those investments are still some distance from paying off.